Skip to main content
BWAY
NASDAQ Industrial Applications And Services

BrainsWay Reports Strong Q1 2026 Results: Revenue Up 35%, Net Income Over 100%, Reaffirms Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.7
Mkt Cap
$675.405M
52W Low
$4.305
52W High
$17.352
52W Position info
288% above low
Off High info
3.8% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

BWAY has more than doubled off its 52-week low of $4.305.

Summary

BrainsWay reported strong Q1 2026 financial results with significant revenue and net income growth, alongside positive operational highlights and reaffirmed full-year guidance.


Key Events · Earnings and Guidance · BWAY

  • Strong Q1 2026 Financial Performance

    Revenue grew approximately 35% year-over-year to $15.5 million, and net income increased by over 100% year-over-year to $2.3 million. Adjusted EBITDA more than doubled to $2.8 million.

  • Reaffirmed Full-Year 2026 Guidance

    The company reiterated its full-year 2026 financial guidance, expecting revenue of $66-$68 million and Adjusted EBITDA of $12-$14 million, indicating continued profitability and growth.

  • Significant Operational Momentum

    Remaining performance obligations grew 25% year-over-year to $75 million, and a record 117 Deep TMS Systems were shipped, representing a 44% increase compared to the prior year.

  • Pipeline Expansion and Payer Support

    BrainsWay secured the first insurer coverage for its accelerated SWIFT™ Deep TMS protocol and plans an FDA filing in Q2 2026 for PTSD symptoms in MDD patients, expanding its clinical pipeline.


Analysis · BWAY · Industrial Applications And Services

BrainsWay delivered robust first-quarter results, significantly exceeding prior-year performance with substantial revenue and net income growth. The company's operational momentum, evidenced by increased system shipments and remaining performance obligations, supports its reaffirmed positive full-year guidance. Strategic investments and an upcoming FDA filing for PTSD further strengthen the long-term growth outlook, indicating continued expansion in its core markets and pipeline.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BWAY was trading at $16.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $675.4M. The 52-week trading range was $4.31 to $17.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BWAY - Latest Insights

BWAY
Nov 10, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $11.67
Real-time Price: $8.40 info
Change: -$3.27 (-28%) info
Market Cap: $360.653M info
BWAY
Sep 29, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.48
Real-time Price: $8.40 info
Change: -$5.08 (-38%) info
Market Cap: $360.653M info
BWAY
Aug 27, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.62
Real-time Price: $8.40 info
Change: -$6.22 (-43%) info
Market Cap: $360.653M info
BWAY
Aug 12, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.00
Real-time Price: $8.40 info
Change: -$6.60 (-44%) info
Market Cap: $360.653M info
BWAY
Jun 29, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $14.48
Real-time Price: $8.40 info
Change: -$6.08 (-42%) info
Market Cap: $360.653M info